Supernus Pharmaceuticals | SUPN - Net Income

Stock Price
56.32
Daily Change
3.02 5.67%
Monthly
14.56%
Yearly
76.50%
Q1 Forecast
49.28

Supernus Pharmaceuticals reported $-45.12M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Abbott USD 1.78B 132M Dec/2025
ANI Pharmaceuticals USD 26.27M 18.13M Sep/2025
Aurora Cannabis CAD -51.47M 36.26M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Canopy Growth CAD -1.64M 39.89M Sep/2025
Cara Therapeutics USD -4.91M 2.77M Mar/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Pacira USD 5.43M 10.28M Sep/2025
Perrigo USD 7.5M 15.9M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Xeris Pharmaceuticals USD 621K 2.55M Sep/2025